Skip to main content
Clinical Trials/NCT01274923
NCT01274923
Unknown
Phase 3

The Effect of Low Intensity Shock Wave Therapy on Erectile Dysfunction in Patients Responding to PDE5i's

Rambam Health Care Campus1 site in 1 country20 target enrollmentAugust 2010

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Erectile Dysfunction
Sponsor
Rambam Health Care Campus
Enrollment
20
Locations
1
Primary Endpoint
International Index of Erectile function- Erectile Function Domain
Last Updated
14 years ago

Overview

Brief Summary

This study aims to evaluate the effect of shockwave therapy on erectile dysfunction on patients responding to PDE5i therapy in a sham controlled randomized double blind manner.

Detailed Description

This study aims to evaluate the effect of a 12-session low intensity shockwave therapy protocol for patients with erectile dysfunction. On screening patients will undergo evaluation by thorough medical history and by questionnaires for evaluation of sexual function. A one-month active treatment with PDE5i will be provided followed by re-evaluation using the same questionnaires. Then another one-month period without PDE5i medication (washout period ) will be done and finally on the following visit evaluation will include the same questionnaires and if fit for inclusion- additional objective evaluation of endothelial function using the Flow mediated dilatation technique and penile blood flow measurement by doppler ultrasound of the Penis will be performed. At the end of this screening pahse the first shock wave session will be performed. Altogether 12 treatment sessions will be performed - 6 treatments twice a week followed by a 3 week no-treatment interval and again 6 treatments twice a week. Follow-up which will include the same evaluation as in the first treatment visit will be performed one month after end of treatment

Registry
clinicaltrials.gov
Start Date
August 2010
End Date
October 2012
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • ED of more than 6 months
  • Rigidity score ≥ 3 under PDE5i therapy
  • SHIM ≤21 under PDE5i therapy
  • Non- hormonal, neurological or psychological pathology
  • Stable heterosexual relationship for more than 3 months

Exclusion Criteria

  • Prior prostatectomy surgery
  • Any unstable medical, psychiatric, spinal cord injury and penile anatomical abnormalities
  • Clinically significant chronic hematological disease
  • Anti-androgens, oral or injectable androgens
  • Radiotherapy in pelvic region

Outcomes

Primary Outcomes

International Index of Erectile function- Erectile Function Domain

Time Frame: At screening and 17 weeks later at last visit

An increase in score of 5points and above will be considered success.

Secondary Outcomes

  • Rigidity scale(At screening and 17 weeks later at last visit)
  • Flow Mediated Dilatation Technique(At screening and 17 weeks later at last visit)

Study Sites (1)

Loading locations...

Similar Trials